ABSI - יחס מחיר להכנסות חזויות Absci

Absci utilizes an AI platform for accelerated drug synthesis, leveraging support from leading pharma behemoths. The expected P/S valuation reflects market expectations, where 1000.40 determines this parameter level. Absci is reducing R&D expenditures in immuno-oncology, monetizing its breakthrough developments through B2B partnerships in the digital antibody design segment.

Valuing Absci (ABSI) assets requires accounting for the synergy between AI-driven antibody design and ESG optimization, which reduces reagent costs. By analyzing the expected P/S ratio, an investor can observe the dynamic business value relative to projected revenue, enabling a real-time assessment of the cloud platform's scaling potential against the risks of overcapitalization or frozen invested capital.